Assessment of Transcatheter Edge-to-Edge Repair in Atrial Functional Mitral Regurgitation (ATRIAL-MR)
Launched by UNIVERSITY HOSPITAL OF COLOGNE · Mar 28, 2025
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The ATRIAL-MR trial is a study looking at how well a specific heart procedure called transcatheter edge-to-edge repair (M-TEER) works for patients with a condition known as atrial functional mitral regurgitation. This condition means that the mitral valve in the heart doesn't close properly, which can lead to blood leaking backward. The study will compare the outcomes of patients who received this procedure to those who chose conservative treatment, which may include medications or lifestyle changes.
To be eligible for this trial, participants should be between the ages of 65 and 74 and have functional mitral regurgitation with a heart function measurement (known as ejection fraction) of 50% or higher. Unfortunately, people under 18 or those with certain heart conditions affecting heart wall movement cannot participate. If you join this trial, you can expect to be part of a study that aims to help doctors understand the best treatment options for this heart condition, contributing to better care for patients in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • functional mitral regurgitation
- • left ventricular ejection fraction ≥50%
- Exclusion Criteria:
- • age under 18 years
- • known regional wall movement disorders
About University Hospital Of Cologne
The University Hospital of Cologne is a leading academic medical center in Germany, renowned for its commitment to advancing healthcare through innovative research and clinical excellence. As a sponsor of clinical trials, the hospital leverages its extensive expertise in various medical fields, collaborating with multidisciplinary teams to conduct rigorous investigations that enhance patient care and contribute to the development of new therapeutic strategies. With state-of-the-art facilities and a strong emphasis on education and training, the University Hospital of Cologne is dedicated to fostering a collaborative environment that promotes ethical research practices and improves health outcomes for diverse patient populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bronx, New York, United States
Barcelona, , Spain
Pisa, , Italy
Kiel, , Germany
Brescia, , Italy
Bordeaux, , France
Toronto, , Canada
Cologne, Nrw, Germany
Hamburg, , Germany
Bad Oeynhausen, , Germany
Bonn, , Germany
Mainz, , Germany
Milan, , Italy
Munich, Bavaria, Germany
Cordoba, , Spain
Nantes, , France
Düsseldorf, , Germany
Leipzig, , Germany
Ulm, , Germany
Leon, , Spain
Oviedo, , Spain
Vigo, , Spain
Patients applied
Trial Officials
Christos Iliadis, MD
Principal Investigator
Heart Center, Department III of Internal Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Kerpener Straße 62, 50937, Cologne, Germany
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported